Katie Kalvaitis
Editorial Director at Healio Cardiac/Vascular Intervention
Editorial Director at Endocrine Today
Editorial Director at Healio
Medical editor & reporter. All tweets my own. @cardiologytoday @gohealio @endocrinetoday @healiowomen
Articles
-
3 days ago |
healio.com | Katie Kalvaitis
Heart disease deaths declined in past 50 years, especially from heart attacks• Overall heart disease mortality among U.S. adults decreased by 66% from 1970 to 2022. • Mortality due to causes other than heart attack increased over time. New data highlight a substantial decline in overall heart disease death rates during the past 50 years, along with a shift in the types of heart disease people are dying from most often.
-
5 days ago |
healio.com | Katie Kalvaitis
Key takeaways: Ecnoglutide is a new GLP-1 receptor agonist being investigated for weight management. Once-weekly therapy also improved cardiometabolic risk factors and reduced liver fat content. CHICAGO — Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in body weight compared with placebo, according to data from the phase 3 SLIMMER study.
-
6 days ago |
healio.com | Katie Kalvaitis
Key takeaways: Zimislecel is an investigational stem cell-derived islet therapy for type 1 diabetes. Ten of 12 participants no longer required insulin at 1 year. Results from this phase 1/2 study support further investigation. CHICAGO — A single infusion of zimislecel, an investigational stem cell-based therapy, restored physiologic islet function and conferred improved outcomes and insulin independence at 1 year in a small study of patients with type 1 diabetes.
-
2 weeks ago |
healio.com | Katie Kalvaitis
• It is important to check lipids early for women and start early intervention. • Experiences unique to women, like age at menarche, contraception and adverse pregnancy outcomes, impact lipids and CVD risk. PHILADELPHIA — Lipid management for woman requires personalized care that considers sex-specific conditions across the reproductive lifespan, particularly during pregnancy, Pam R.
-
2 weeks ago |
healio.com | Katie Kalvaitis
Four recent cardiometabolic research updates you should know• GLP-1 benefits persist regardless of background SGLT2 inhibitor use. • New insights into the mechanistic effects of mineralocorticoid receptor antagonists. PHILADELPHIA — During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation that advance the field of cardiometabolic research.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 252
- Tweets
- 643
- DMs Open
- No
🔥Highlights from day 2 #ACC25 All @GoHealio @CardiologyToday coverage here: https://t.co/5HC8F2VhYj 📌 ALPACA: https://t.co/ZKlRymszwc 📌 BHF PROTECT-TAVI: https://t.co/6pkwuVdqrd 📌 FRESH-UP: https://t.co/kkPhuVXflt 📌 Evolut Low Risk at 5 years, DapaTAVI & more below
Positive data for lepodisiran presented at #ACC25: 📌 resulted in substantial reductions in lipoprotein(a) at 6 months and 1 year vs placebo in phase 2 study 📌 drug will allow infrequent administration 📌 a cardiovascular outcomes trial is underway More in the link below
#Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more than 90 percentage points with a single 400-mg dose compared with placebo @CleClinicHVTI @ACCinTouch #ACC25 #cardiotwitter https://t.co/JfvTFheKsj
New 5-year data from Evolut Low Risk Trial: 📌 At 5 years, no difference in death or disabling stroke between TAVR and surgery in patients at low surgical risk 📌 Both groups had improved QoL 📌 “These results are very encouraging for the TAVR population” More in link below
Among patients with severe aortic stenosis at low surgical risk, TAVR and surgery conferred similar rates of death and disabling stroke at 5 years, new data from the Evolut Low Risk Trial show @HMethodistCV @WeillCornell @ACCinTouch #ACC25 https://t.co/FomgFGMVvR